Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron; Annelie E. Abrahamsson; Charlene F. Barroga; Edward Kavalerchik; Jason Gotlib; John D. Hood; Jeffrey Durocher; Chi Ching Mak; Glenn Noronha; Richard M. Soll; Ayalew Tefferi; Ken Kaushansky; Catriona H.M. Jamieson

doi:10.1016/j.ccr.2008.02.017

Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors

Ifat Geron, Annelie E. Abrahamsson, Charlene F. Barroga, Edward Kavalerchik, Jason Gotlib, John D. Hood, Jeffrey Durocher, Chi Ching Mak, Glenn Noronha, Richard M. Soll, Ayalew Tefferi, Ken Kaushansky, Catriona H.M. Jamieson

Hematology

Research output: Contribution to journal › Article

107 Scopus citations

Abstract

Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia. In this study, JAK2V617F expression by human hematopoietic progenitors promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immunocompromised mouse transplantation model. A selective JAK2 inhibitor, TG101348 (300 nM), significantly inhibited JAK2V617F⁺ progenitor-derived colony formation as well as engraftment (120 mg/kg) in xenogeneic transplantation studies. TG101348 treatment decreased GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F⁺ progenitor differentiation, and inhibited STAT5 as well as GATA S310 phosphorylation. Thus, TG101348 may be an effective inhibitor of JAK2V617F⁺ MPDs in clinical trials.

Original language	English (US)
Pages (from-to)	321-330
Number of pages	10
Journal	Cancer cell
Volume	13
Issue number	4
DOIs	https://doi.org/10.1016/j.ccr.2008.02.017
State	Published - Apr 8 2008

Keywords

CELLCYCLE
CHEMBIO
STEMCELL

ASJC Scopus subject areas

Oncology
Cell Biology
Cancer Research

Access to Document

10.1016/j.ccr.2008.02.017

Fingerprint Dive into the research topics of 'Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors'. Together they form a unique fingerprint.

Cite this

Geron, I., Abrahamsson, A. E., Barroga, C. F., Kavalerchik, E., Gotlib, J., Hood, J. D., Durocher, J., Mak, C. C., Noronha, G., Soll, R. M., Tefferi, A., Kaushansky, K., & Jamieson, C. H. M. (2008). Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors. Cancer cell, 13(4), 321-330. https://doi.org/10.1016/j.ccr.2008.02.017

Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors. / Geron, Ifat; Abrahamsson, Annelie E.; Barroga, Charlene F.; Kavalerchik, Edward; Gotlib, Jason; Hood, John D.; Durocher, Jeffrey; Mak, Chi Ching; Noronha, Glenn; Soll, Richard M.; Tefferi, Ayalew; Kaushansky, Ken; Jamieson, Catriona H.M.

In: Cancer cell, Vol. 13, No. 4, 08.04.2008, p. 321-330.

Research output: Contribution to journal › Article

Geron, Ifat ; Abrahamsson, Annelie E. ; Barroga, Charlene F. ; Kavalerchik, Edward ; Gotlib, Jason ; Hood, John D. ; Durocher, Jeffrey ; Mak, Chi Ching ; Noronha, Glenn ; Soll, Richard M. ; Tefferi, Ayalew ; Kaushansky, Ken ; Jamieson, Catriona H.M. / Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors. In: Cancer cell. 2008 ; Vol. 13, No. 4. pp. 321-330.

@article{cfe13717dccd4a5f885f4bc4b9937d5b,

title = "Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors",

abstract = "Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia. In this study, JAK2V617F expression by human hematopoietic progenitors promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immunocompromised mouse transplantation model. A selective JAK2 inhibitor, TG101348 (300 nM), significantly inhibited JAK2V617F+ progenitor-derived colony formation as well as engraftment (120 mg/kg) in xenogeneic transplantation studies. TG101348 treatment decreased GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibited STAT5 as well as GATA S310 phosphorylation. Thus, TG101348 may be an effective inhibitor of JAK2V617F+ MPDs in clinical trials.",

keywords = "CELLCYCLE, CHEMBIO, STEMCELL",

author = "Ifat Geron and Abrahamsson, {Annelie E.} and Barroga, {Charlene F.} and Edward Kavalerchik and Jason Gotlib and Hood, {John D.} and Jeffrey Durocher and Mak, {Chi Ching} and Glenn Noronha and Soll, {Richard M.} and Ayalew Tefferi and Ken Kaushansky and Jamieson, {Catriona H.M.}",

year = "2008",

month = apr,

day = "8",

doi = "10.1016/j.ccr.2008.02.017",

language = "English (US)",

volume = "13",

pages = "321--330",

journal = "Cancer Cell",

issn = "1535-6108",

publisher = "Cell Press",

number = "4",

}

TY - JOUR

T1 - Selective Inhibition of JAK2-Driven Erythroid Differentiation of Polycythemia Vera Progenitors

AU - Geron, Ifat

AU - Abrahamsson, Annelie E.

AU - Barroga, Charlene F.

AU - Kavalerchik, Edward

AU - Gotlib, Jason

AU - Hood, John D.

AU - Durocher, Jeffrey

AU - Mak, Chi Ching

AU - Noronha, Glenn

AU - Soll, Richard M.

AU - Tefferi, Ayalew

AU - Kaushansky, Ken

AU - Jamieson, Catriona H.M.

PY - 2008/4/8

Y1 - 2008/4/8

N2 - Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia. In this study, JAK2V617F expression by human hematopoietic progenitors promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immunocompromised mouse transplantation model. A selective JAK2 inhibitor, TG101348 (300 nM), significantly inhibited JAK2V617F+ progenitor-derived colony formation as well as engraftment (120 mg/kg) in xenogeneic transplantation studies. TG101348 treatment decreased GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibited STAT5 as well as GATA S310 phosphorylation. Thus, TG101348 may be an effective inhibitor of JAK2V617F+ MPDs in clinical trials.

AB - Polycythemia Vera (PV) is a myeloproliferative disorder (MPD) that is commonly characterized by mutant JAK2 (JAK2V617F) signaling, erythrocyte overproduction, and a propensity for thrombosis, progression to myelofibrosis, or acute leukemia. In this study, JAK2V617F expression by human hematopoietic progenitors promoted erythroid colony formation and erythroid engraftment in a bioluminescent xenogeneic immunocompromised mouse transplantation model. A selective JAK2 inhibitor, TG101348 (300 nM), significantly inhibited JAK2V617F+ progenitor-derived colony formation as well as engraftment (120 mg/kg) in xenogeneic transplantation studies. TG101348 treatment decreased GATA-1 expression, which is associated with erythroid-skewing of JAK2V617F+ progenitor differentiation, and inhibited STAT5 as well as GATA S310 phosphorylation. Thus, TG101348 may be an effective inhibitor of JAK2V617F+ MPDs in clinical trials.

KW - CELLCYCLE

KW - CHEMBIO

KW - STEMCELL

UR - http://www.scopus.com/inward/record.url?scp=41249098776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41249098776&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2008.02.017

DO - 10.1016/j.ccr.2008.02.017

M3 - Article

C2 - 18394555

AN - SCOPUS:41249098776

VL - 13

SP - 321

EP - 330

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 4

ER -